|
Genuv Teams With Nanocarry Therapeutics to Develop Novel anti-PD-1 mAb Treatments That Can Cross the Blood-Brain Barrier
SEOUL, South Korea & NESS ZIONA, Israel--(BUSINESS WIRE)--Genuv Inc., a clinical-stage biotechnology company focused on innovative drug discovery for central nervous system disorders and advanced antibody therapies, and Nanocarry Therapeutics, a private company developing a new class of therapeutics capable of crossing the Blood-Brain Barrier (BBB), announced an agreement to collaborate on the development of an experimental drug to treat metastatic lung cancer. Specifically, this collaboration will further develop GNUV201 to treat metastatic tumors in the brain, using Nanocarry’s AxS platform to cross the BBB.
…
To view original article, please click here.
|
